1-2 of 2
Kirsten Van Hoorde
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 MCL cohort

Free
Marie José Kersten, Joost Vermaat, Pim Mutsaers, Maria Kuipers, Evelyne Willems, Sébastien Anguille, Tim Dekker, Caron Jacobson, Michael Bishop, Peter Vandenberghe, Guillaume Dachy, Andreas Klein, Jon Arnason, Stavros Milatos, Chiara Lobetti-Bodoni, Eva Santermans, Sandra Blum, Kirsten Van Hoorde, Maike Spoon, Omotayo Fasan, Martin Dreyling
Journal: Blood
Blood (2025) 146 (Supplement 1): 662.
https://doi.org/10.1182/blood-2025-662
Published: 2025
Journal Articles

Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT

Free
Valentin Ortiz-Maldonado, Nuria Martínez-Cibrián, Leticia Alserawan, Sergi Betriu, Ana Triguero, Sandra Blum, Margaux Faes, Marte C. Liefaard, Margot J. Pont, Maike Spoon, Kirsten Van Hoorde, Anna D. D. van Muyden, Julio Delgado, Natalia Tovar
Journal: Blood
Blood (2024) 144 (Supplement 1): 3452.
https://doi.org/10.1182/blood-2024-207546
Published: 2024